Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Sep;28(9):1922-6.
doi: 10.1038/leu.2014.155. Epub 2014 May 12.

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

A Rocci  1 , C C Hofmeister  2 , S Geyer  2 , A Stiff  2 , M Gambella  1 , L Cascione  3 , J Guan  4 , D M Benson  2 , Y A Efebera  2 , T Talabere  2 , V Dirisala  2 , E M Smith  2 , P Omedè  1 , G Isaia  5 , L De Luca  6 , D Rossi  7 , S Gentili  8 , G Uccello  8 , J Consiglio  2 , R Ria  8 , G Benevolo  8 , S Bringhen  1 , V Callea  8 , B Weiss  9 , A Ferro  10 , V Magarotto  1 , H Alder  4 , J C Byrd  2 , M Boccadoro  2 , G Marcucci  1 , A Palumbo  1 , F Pichiorri  2
Affiliations

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

A Rocci et al. Leukemia. 2014 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None of the authors have a relevant conflict of interest to report.

Figures

Figure 1
Figure 1
(A) Supervised clustering analysis representative of the 800 miRNAs assessed using NanoString nCounter Technology and analyzed in 54 MM patients. Red cells indicate high expression and blue cells indicate low expression (B) list of the 25 miRNAs identified to be consistently expressed in at least 20% of MM samples analyzed. Overall survival (OS) for low vs. high expressors log2 S-miR-16 (C) and S-miR-25 (D) expression value were used to build OS curves. The median value of S-miR-16 and S-miR-25 for the healthy normal subjects was used as the cutoff expression value.
See this image and copyright information in PMC

References

    1. Kumar SK, Uno H, Jacobus SJ, Van Wier SA, Ahmann GJ, Henderson KJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2011 Oct 20;118(16):4359–4362. - PMC - PubMed
    1. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2008 Sep 2;105(35):12885–12890. - PMC - PubMed
    1. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer. 2009 Jun;48(6):521–531. - PubMed
    1. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009 Dec 10;114(25):e20–26. - PubMed
    1. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. Journal of Clinical Oncology 2010. 2010 Dec 1;28(34):5101–5109. - PubMed

Publication types